Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 15 items

CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns

Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. , Wu, Y. ... - EHA - Haematologica - 2010

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-8525 , CALGB-10201 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9665 , CALGB-9720

Prognostic impact of the 2017 European Leukemianet (ELN) classification of adult patients (pts) with acute myeloid leukemia (AML) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols

Bill, Marius , Mrózek, K , Kohlschmidt, J. , Nicolet, D. ... - EHA - HemaSphere - 2019

Abstract - Secondary-not-in-original - Meta-Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-20202 , CALGB-9665

Validation of the prognostic significance of the knowledge bank (KB) algorithm in adult acute myeloid leukemia (AML) patients (pts) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols and suggestions for improvements

Bill, Marius , Mrózek, Krzysztof , Kohlschmidt, Jessica ... - EHA - EHA Library - 2020

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Clinical impact of ABL1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB 10001 and 9665 (Alliance)

DeBoer, Rebecca , Mulkey, Flora , Koval, Gregory , Wetzler, Meir ... - EHA - Haematologica - 2014

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10001 , CALGB-9665

Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603)

Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019

Abstract - Secondary-not-in-original - Primary - Leukemia - ACOSOG-Z901101

Genetic landscape of FLT3-mutated acute myeloid leukemia (AML) patients treated within the ratify trial (Alliance C10603)

Jahn, Nikolaus , Panina, Ekaterina , Bullinger, Lars , Dolnik, Anna ... - EHA - HemaSphere - 2019

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-10603

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study

Marcucci, G. , Maharry, K. S. , Wu, Y. , Radmacher, M. D. ... - EHA - Haematologica - 2010

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

TET2 mutations occur in over 20% of adults with de novo cytogenetically normal AML, and their prevalence increases with age: A Cancer and Leukemia Goup B study.

Metzeler, K. H. , Maharry, K. , Margeson, D. , Curfman, J. ... - EHA - Haematologica - 2010

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

High expression of DNMT3B negatively impacts on clinical outcome of older patients (pts) with primary cytogenetically normal (CN) acute myeloid leukemia (AML) [CALGB 20202 (Alliance)].

Niederwieser, C. , Kohlschmidt, J. , Maharry, K. , Mrózek, K. ... - EHA - European Hematology Association Congress - 2013

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-20202

Long non-coding RNA profiling provides important prognostic information and biologic insights in younger patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML) (Alliance) CALGB 8461, 9665, and 20202.

Papaioannou, Dimitrios , Nicoleta, Deedra , Volinia, Stefano ... - EHA - - 2016

Abstract - Secondary - Meta-Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Prognostic and biologic significance of circular RNA profiling in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML) (CALGB/Alliance 8461, 9665, 20202)

Papaioannou, Dimitrios , Volinia, Stefano , Nicolet, Deedra ... - EHA - - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Prognostic impact of NPM1 mutations in cytogenetically normal (CN) acute myeloid leukemia (AML) is adversely affected by high expression of the ERG gene: A Cancer and Leukemia Group B (CALGB) study

Paschka, P. , Marcucci, G. , Maharry, K. S. , Whitman, S. P. ... - EHA - Haematol-Hematol J - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

The Addition of Ixazomib (IXA) to Pomalidomide (POM) and Dexamethasone (DEX) Improves Progression-Free Survival (PFS) for Multiple Myeloma (MM) Patients (Pts) Progressing on Lenalidomide (LEN) as Part of 1st Line Therapy: Results of the Randomized Phase II Alliance Study A061202

Voorhees, Peter , Suman, Vera , Efebera, Yvonne , Raje, Noopur ... - EHA - Hemasphere - 2022

Abstract - Primary - Primary - Myeloma - Alliance-A061202

Ratify (Alliance 10603): Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin Plus Standard Chemotherapy

Voso, Maria Teresa , Larson, Richard A. , Prior, Thomas W ... - EHA - HemaSphere - 2019

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603